Understanding Acute Myelogenous Leukemia Treatment Options

Acute myelogenous leukemia treatment focuses on eliminating cancerous cells in the bone marrow while improving health and well-being. Advancements in oncology have led to a range of effective treatment options, including standard therapies and emerging approaches through clinical trials. By tailoring treatment plans, an oncologist can help patients manage this aggressive form of leukemia and, in the best cases, help them achieve remission.

Standard acute myelogenous leukemia treatments

Standard treatment options for acute myelogenous leukemia (AML) aim to destroy leukemia cells, restore healthy blood cell production, and achieve long-term remission. The most commonly used therapies include chemotherapy, targeted therapy, and radiation therapy, often in combination, depending on the specifics of the patient's condition. An oncologist will select an acute myelogenous leukemia treatment based on the subtype of AML, genetic mutations, overall health, and response to initial therapy, among other factors.

Chemotherapy

Chemotherapy remains the primary treatment for AML, using powerful drugs to eliminate leukemia cells in the bone marrow and bloodstream. This treatment is typically administered in phases, starting with induction therapy to rapidly reduce cancerous cells, followed by consolidation therapy to maintain remission and prevent relapse.

The induction phase of chemotherapy often involves a combination of cytarabine and an anthracycline drug, such as daunorubicin or idarubicin. This regimen eliminates as many leukemia cells as possible. Following this phase, the patient may need to undergo additional cycles of chemotherapy to destroy any remaining cancer cells and reduce the risk of recurrence.

While chemotherapy effectively targets leukemia, it can also impact healthy blood cells, which can cause temporary side effects such as fatigue, nausea, and an increased risk of infections. Supportive care, such as blood transfusions and immune-boosting medications, can help manage these side effects and improve the patient's tolerance to their treatment.

Targeted therapy

Targeted therapy is an advanced approach focusing on specific genetic abnormalities in leukemia cells. While chemotherapy affects both cancerous and healthy cells, targeted therapies only interfere with the mechanisms that allow leukemia cells to grow and survive.

Targeted therapy is often combined with chemotherapy or used as a treatment option for patients who are unable to tolerate intensive chemotherapy. By focusing on the unique genetic features of leukemia, targeted therapies provide a more personalized approach to treatment with fewer side effects than chemotherapy.

Radiation therapy

Although radiation therapy is not a primary acute myelogenous leukemia treatment, it can address localized areas of leukemia. High-energy radiation targets and destroys cancer cells, making it particularly beneficial for patients with leukemia that has spread to the brain, spinal cord, or other areas outside the bone marrow. It is carefully planned to minimize exposure to surrounding healthy tissues. While side effects such as skin irritation and fatigue can occur, they are typically manageable with supportive care strategies.

In preparation for a stem cell transplant, radiation therapy may also be used to eliminate remaining leukemia cells and suppress the immune system to prevent transplant rejection. This conditioning treatment, often combined with high-dose chemotherapy, enhances the success of the transplant by creating space for new, healthy stem cells to grow.

Emerging treatments and clinical trials

Research into acute myelogenous leukemia treatment continues to expand, leading to innovative therapies that improve outcomes and reduce side effects. Patients can typically access these therapies through clinical trials if eligible. Such trials also focus on novel drug combinations, optimizing existing treatments to improve remission rates and reduce toxicity.

Immunotherapy is one of the most exciting areas of AML research. This approach enhances the body's immune system to recognize and attack leukemia cells more effectively. A monoclonal antibody, such as gemtuzumab ozogamicin, targets specific proteins in leukemia cells, delivering chemotherapy directly to cancer cells while sparing healthy cells.

Managing the side effects of acute myelogenous leukemia treatment

Acute myelogenous leukemia treatments, while effective, can cause side effects that affect daily life. An oncologist can help patients manage these side effects, but it remains important to be aware of them ahead of time. Common examples include:

• Bruising and bleeding easily
• Skin rashes and mouth sores
• Digestive issues
• Hair loss
• Fatigue 

Emotional well-being is another important aspect of managing AML. Support groups, counseling, and open communication with healthcare providers can help address emotional challenges and provide encouragement throughout treatment.

Explore acute myelogenous leukemia treatment options

Through acute myelogenous leukemia treatment, oncologists can help improve survival rates and enhance quality of life. With various standard treatments, emerging therapies, and supportive care options available, personalized treatment plans are designed to achieve better health outcomes. To explore your or your loved one's options, contact an oncologist at Lindenberg Cancer & Hematology Center today and schedule an appointment.

Request an appointment here: https://lindenbergcancer.com or call Lindenberg Cancer & Hematology Center at (856) 475-0876 for an appointment in our Marlton office.

Check out what others are saying about our services on Yelp: Acute Myelogenous Leukemia Treatment in Marlton, NJ.